Zusammenfassung
Gegenwärtig überleben ungefähr 60% der erwachsenen und 80% der jugendlichen Patienten mit Krebs 5 Jahre nach Diagnose. Bei ungefähr zwei Drittel dieser Langzeitüberlebenden nach Krebstherapie wird mindestens eine Spättoxizität und bei einem Drittel eine schwere oder lebensbedrohliche Spättoxizität beobachtet. Das Ziel der aktuellen Krebstherapie ist daher sowohl die Heilung des Patienten von der vorliegenden Krebserkrankung, als auch eine Reduktion des Auftretens von Folgeschäden der Behandlung, um damit eine bestmögliche langfristige Lebensqualität des Patienten zu erreichen. In der vorliegenden Arbeit werden auf Grundlage aktueller Ergebnisse typische Beispiele für Spätschäden nach Chemotherapie bei langzeitüberlebenden Tumorpatienten diskutiert.
Abstract
Today, about 60% of adult patients and 80% children diagnosed with cancer will survive 5 years after diagnosis. Approximately two thirds of cancer survivors will experience at least one late effect, and about one third severe or life threatening late effects. The aim of cancer treatment today is to cure the malignant disease but at the same time, to minimize the incidence of post-treatment complications.
In the current overview we summarize, based on the most recent publications, typical late effects in cancer survivors.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Ades L, Guardiola P, Socie G (2002) Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev 16: 135–146
Bastie JN, Cazals-Hatem D, Daniel MT et al. (1999) Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment. Leuk Lymphoma 35: 555–565
Bonadonna G, Viviani S, Bonfante V et al. (2005) Survival in Hodgkin’s disease patients — report of 25 years of experience at the Milan Cancer Institute. Eur J Cancer 41: 998–1006
Brown JR, Yeckes H, Friedberg JW et al. (2005) Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin’s lymphoma. J Clin Oncol 23: 2208–2214
Eigen H, Wyszomierski D (1985) Bleomycin lung injury in children: pathophysiology and guidlines for management. Am J Pediatr Hematol Oncol 7: 71–79
Franchini M, Gandini G, Veneri D et al. (2004) Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia. Transfusion 44: 833–837
Lipshultz SE, Sallan SE (1993) Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol 11: 1199–1203
Lipshultz SE, Rifai N, Dalton VM et al. (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351: 145–153
Locasciulli A, Testa M, Valsecchi MG et al. (1999) The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group. Transplantation 68: 1486–1491
McKeage K, Perry CM (2002) Trastuzumab. Drugs 62: 209–243
Metayer C, Curtis RE, Vose J et al. (2003) Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood 101: 2015–2023
Nichols CR, Breeden ES, Loehrer PJ et al. (1993) Secondary leukemia associated with a conventional dose of etoposide. J Natl Cancer Inst 85: 36–40
Ng AK, Bernardo MV, Weller E et al. (2002) Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 100: 1989–1996
Pihkala J, Saarinen UM, Lundstrom U et al. (1996) Myocardial function in children and adolescents after therapy with anthracyclines and chest irradiation. Eur J Cancer 32A: 97–103
Schmid P, Possinger K (2001) Liposomal anthracycline for improved cardiac tolerability. Breast 10 [Suppl 2]: 22–27
Shapiro CL, Hardenbergh PH, Gelman R et al. (1998) Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 16: 3493–3501
Smith SM, Le Beau MM, Huo D et al. (2003) Clincal-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 102: 43–52
Stewart JR, Fajardo LF, Gillette SM et al. (1995) Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31: 1205–1211
Swain SM, Whaley FS, Ever MS (2003) Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97: 2869–2879
Veinot JP, Edwards WD (1996) Pathology of radiation-induced heart disease: A surgical and autopsy study of 27 cases. Hum Pathol 27: 766–773
Von Hoff DD, Layard MW, Basa P et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 91: 710–717
Interessenkonflikt:
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pönisch, W., Niederwieser, D. Folgeerkrankungen nach Chemotherapie. Internist 47, 266–274 (2006). https://doi.org/10.1007/s00108-006-1577-z
Issue Date:
DOI: https://doi.org/10.1007/s00108-006-1577-z